ANG-003 is under clinical development by Anagram Therapeutics and currently in Phase I for Exocrine Pancreatic Insufficiency. According to GlobalData, Phase I drugs for Exocrine Pancreatic Insufficiency does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ANG-003 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ANG-003 overview

ANG-003 is under development for the treatment of malabsorption syndromes and exocrine pancreatic insufficiency in patients with cystic fibrosis. The drug candidate is orally delivered non-porcine enzyme replacement therapy (ERT). It consists of a combination of three purified enzymes (lipase, protease, and amylase).

Anagram Therapeutics overview

Anagram Therapeutics (Anagram) formerly Synspira Therapeutics (Synspira Therapeutics) is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis and other rare diseases where there is a high unmet treatment need. The company is headquartered in Framingham, Massachusetts, the US.

For a complete picture of ANG-003’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.